Home Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt
Article
Licensed
Unlicensed Requires Authentication

Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt

  • Mohamed A. El Far , Mohamed A. Atwa , Raida S. Yahya and Mohamed A. El Basuni
Published/Copyright: May 8, 2006

Abstract

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-induced death. Somatic mutation of the p53 gene is the most common genetic abnormality so far described in human cancer and there is evidence that supports a high level of p53 alterations in HCC. The aim of this study was to investigate serum levels of p53 in Egyptian patients with HCC, and its relation to other prognostic factors such as tumor grade, α-fetoprotein (AFP), and liver function tests in an attempt to clarify their significance in the pathogenesis of the disease. Liver function tests were carried out and AFP and p53 levels were measured for all individuals studied. Our results show that detection of p53 increased the frequency of HCC prediction from 79.5% to 86.3%. Moreover, significant positive correlation between p53 and tumor size (cm) for tumor grade II and III was identified. In conclusion, serum concentration of p53 protein may be a convenient and useful non-invasive screening test for prediction of HCC.


Corresponding author: Professor Mohamed A. El Far, Division of Biochemistry, Faculty of Sciences, Mansoura University, Mansoura, Egypt Phone: +20-10-1562520, Fax: +20-50-2246781,

References

1. Vauthey JN. Hepatobiliary cancer. Cancer Control 1998; 5:32–3.10.1177/107327489800503S12Search in Google Scholar

2. Oka H, Kurioka N, Kim K, Kanno T, Kuroki K, Mizguchi Y, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12:680–7.10.1002/hep.1840120411Search in Google Scholar

3. London TW. Hepatocellular carcinoma. Etiology and pathology. In: Proceedings of the ASCO 34th annual meeting, Los Angeles, CA, May 1998:168–75.Search in Google Scholar

4. Hsu YL, Kuo PL, Chiang LC, Lin CC. Involvement of p53, nuclear factor κB and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin d in human hepatoma cell lines. Cancer Lett 2004; 213:213–21.10.1016/j.canlet.2004.03.044Search in Google Scholar

5. Volkmann M, Hofmann WJ, Muller M, Karth U, Otto G, Zentgraf H, et al. p53 over-expression is frequent in Europeans in hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 1994; 9:195–204.Search in Google Scholar

6. Lui WY, Chiu ST, Chiu JH, Loong CC, Chau GY, King KL, et al. Evaluation of a simplified staging system for prognosis of hepatocellular carcinoma. J Formos Med Assoc 1999; 98:248–53.Search in Google Scholar

7. Peng SY, Chen WJ, Lai PL, Jeng YMS. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004; 112:44–50.10.1002/ijc.20279Search in Google Scholar

8. Kannangai R, Wang J, Liu QZ, Sahin F, Torbenson M. Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer 2005; 35:53–60.10.1385/IJGC:35:1:053Search in Google Scholar

9. Reeves ME, De Matteo RB. Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol 2000; 19:84–93.10.1002/1098-2388(200009)19:2<84::AID-SSU2>3.0.CO;2-0Search in Google Scholar

10. Okada T, Iizuka N, Yamada-Okabe H, Mori N, Tamesa T, Takemoto N, et al. Gene expression profile linked to p53 status in hepatitis C virus-related hepatocellular carcinoma. FEBS Lett 2003; 555:583–90.10.1016/S0014-5793(03)01345-0Search in Google Scholar

11. Cho JW, Park K, Kweon GR, Park JC, Lee JC, Baek WK, et al. Modulation of cell death sensitivity by mutant p53 in HCV core-expressing cells. Int J Mol Med 2005; 15:475–80.10.3892/ijmm.15.3.475Search in Google Scholar

12. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26(Suppl 1):345–85.10.1002/hep.510260706Search in Google Scholar

13. Lin J, Zhu MH, Qu JH, Li FM, Ni CR. Effects of hepatitis B virus X gene on p21(WAF1) expression through p53-dependent and p53-independent pathways. Ai Zheng 2004; 23:749–55.Search in Google Scholar

14. Okada S, Sato T, Okusaka T, Ikeda M, Nakasuka H, Kosakamoto H, et al. Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease. Br J Cancer 1998; 77:2028–31.10.1038/bjc.1998.337Search in Google Scholar

15. Shieh YS, Nguyen C, Vocal MV, Chu H. Tumor suppressor p53 gene in hepatitis C and B virus associated human HCC. Int J Cancer 1993; 54:558–62.10.1002/ijc.2910540407Search in Google Scholar PubMed

16. Ray RB, Steele R, Meyer K, Ray R. Transcription repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997; 272:10983–6.10.1074/jbc.272.17.10983Search in Google Scholar PubMed

Received: 2005-8-31
Accepted: 2006-2-6
Published Online: 2006-5-8
Published in Print: 2006-5-1

©2006 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. CCLM: Expanding the science worldwide
  2. Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening
  3. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective
  4. De novo deletion removes a conserved motif in the C-terminus of ABCA4 and results in cone-rod dystrophy
  5. Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients
  6. Influence of human haptoglobin polymorphism on oxidative stress induced by free hemoglobin on red blood cells
  7. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia
  8. Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
  9. A longitudinal evaluation of urinary glycosaminoglycan excretion in normoalbuminuric type 1 diabetic patients
  10. National survey on the execution of the oral glucose tolerance test (OGTT) in a representative cohort of Italian laboratories
  11. The reduction of cholesteryl linoleate in lipoproteins: an index of clinical severity in β-thalassemia/Hb E
  12. Alterations in serum glycosaminoglycan profiles in Graves' patients
  13. Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic lateral sclerosis (SALS) and familial ALS patients
  14. Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera
  15. Utilizing ultrafiltration to remove alkaline phosphatase from clinical analyzer water
  16. Measurement of serum monoclonal components: comparison between densitometry and capillary zone electrophoresis
  17. Salivary aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase: possible markers in periodontal diseases?
  18. Reticulocyte count, mean reticulocyte volume, immature reticulocyte fraction, and mean sphered cell volume in elite athletes: reference values and comparison with the general population
  19. Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece
  20. The effects of adrenocorticotrophic hormone and cortisol on homocysteine and vitamin B concentrations
  21. Plasma, salivary and urinary cotinine in non-smoker Italian women exposed and unexposed to environmental tobacco smoking (SEASD study)
  22. Cut-off values for total serum immunoglobulin E between non-atopic and atopic children in north-west Croatia
  23. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures
  24. Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt
  25. Insufficient filling of vacuum tubes as a cause of microhemolysis and elevated serum lactate dehydrogenase levels. Use of a data-mining technique in evaluation of questionable laboratory test results
  26. Evaluation of three different specimen types (serum, plasma lithium heparin and serum gel separator) for analysis of certain analytes: clinical significance of differences in results and efficiency in use
  27. Comparative evaluation of a new immunoradiometric assay for corticotropin
  28. Mast cells in atherosclerosis as a source of the cytokine RANKL
  29. Falsely increased total serum protein due to dextran interference
Downloaded on 13.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2006.091/html
Scroll to top button